ScholarIQanswers from OpenAlex
Rapt Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Rapt Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Rapt Therapeutics (United States)?
ScholarIQrecord summary
Rapt Therapeutics (United States) is a research organisation in South San Francisco, US. OpenAlex records 530 works and 74,805 citations for it. 614 researchers list it as their most recent affiliation.
How many works does Rapt Therapeutics (United States) have?
ScholarIQindexed works
Rapt Therapeutics (United States) has 530 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rapt Therapeutics (United States) have?
ScholarIQcitation count
Rapt Therapeutics (United States) has 74,805 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Rapt Therapeutics (United States)?
ScholarIQresearcher count
Rapt Therapeutics (United States) has 614 researchers in the ScholarIQ index.
What is the average h-index at Rapt Therapeutics (United States)?
ScholarIQavg h-index
Rapt Therapeutics (United States) has an average h-index of 68.8 in OpenAlex.
What is the ROR of Rapt Therapeutics (United States)?
ScholarIQror
The ROR for Rapt Therapeutics (United States) is on the source record.
What is the OpenAlex record for Rapt Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Rapt Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Rapt Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Rapt Therapeutics (United States)?
ScholarIQmost cited works
Functional Characterization of the <i>S. cerevisiae</i> Genome by Gene Deletion and Parallel Analysis
Elizabeth A. Winzeler, Daniel Shoemaker, Anna Astromoff, Hong Liang, Keith M. Anderson, Bruno André, Rhonda Bangham, Rocío Benito, Jef D. Boeke, Howard Bussey, Angela Chu, Carla J. Connelly, Karen Davis, Fred S. Dietrich, Sally Dow, Mohamed El Bakkoury, Françoise Foury, Stephen Friend, Erik Gentalen, Guri Giaever, Johannes H. Hegemann, Ted Jones, Michael T. Laub, Hong Liao, Nicole Liebundguth, David J. Lockhart, Anca Lucau‐Danila, Marc Lussier, Nasiha M’Rabet, P Ménard, Michael Mittmann, Chai Pai, Corinne Rebischung, José Luis Revuelta, Linda Riles, Christopher J. Roberts, Petra Ross‐Macdonald, Bart Scherens, M Snyder, Sharon Sookhai-Mahadeo, Reginald Storms, Steeve Véronneau, Marleen Voet, Guido Volckaert, Teresa R. Ward, Robert Wysocki, Grace S. Yen, Kexin Yu, Katja Zimmermann, Peter Philippsen, Mark Johnston, Ronald W. Davis
Generation of superoxide by purified brain nitric oxide synthase.
Sovitj Pou, Wanida S. Pou, David S. Bredt, Solomon H. Snyder, Gerald M. Rosen
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
John Welsh, Patrick P. Zarrinkar, Lisa M. Sapinoso, S Kern, Cynthia Behling, Bradley J. Monk, David J. Lockhart, Robert A. Burger, Garret M. Hampton
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Dominique P. Germain, Derralynn Hughes, Kathy Nicholls, Daniel G. Bichet, Roberto Giugliani, William R. Wilcox, Claudio Feliciani, Suma P. Shankar, Fatih Süheyl Ezgü, Hernan Amartino, Drago Bratkovic, Ulla Feldt‐Rasmussen, Khan Nedd, Usama Sharaf El Din, Charles Marques Lourenço, Maryam Banikazemi, Joel Charrow, Majed Dasouki, David N. Finegold, Pilar Giraldo, Özlem Göker-Alpan, Nicola Longo, C. Ronald Scott, Roser Torrá, Ahmad Tuffaha, Ana Jovanović, Stephen Waldek, Seymour Packman, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Elfrida R. Benjamin, Franklin K. Johnson, David J. Lockhart, Nina Skuban, Jeff Castelli, Jay Barth, Carrolee Barlow, Raphael Schiffmann
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn Hughes, Kathy Nicholls, Suma P. Shankar, Gere Sunder–Plassmann, David M. Koeller, Khan Nedd, Gerard Vockley, Takashi Hamazaki, Robin Lachmann, Toya Ohashi, Iacopo Olivotto, Norio Sakai, Patrick Deegan, David Dimmock, François Eyskens, Dominique P. Germain, Özlem Göker-Alpan, É. Hachulla, Ana Jovanović, Charles Marques Lourenço, Ichiei Narita, Mark Thomas, William R. Wilcox, Daniel G. Bichet, Raphael Schiffmann, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Franklin K. Johnson, Pol Boudes, Elfrida R. Benjamin, David J. Lockhart, Carrolee Barlow, Nina Skuban, Jeffrey P. Castelli, Jay Barth, Ulla Feldt‐Rasmussen
How much of the research on Rapt Therapeutics (United States) is open access?
ScholarIQopen access share
75%OPEN ACCESS